Gilead Sciences
GILD
1,483 hedge funds and large institutions have $70.3B invested in Gilead Sciences in 2019 Q2 according to their latest regulatory filings, with 112 funds opening new positions, 566 increasing their positions, 652 reducing their positions, and 103 closing their positions.
11% more funds holding in top 10
Funds holding in top 10: 44 → 49 (+5)
6% more capital invested
Capital invested by funds: $66.2B → $70.3B (+$4.09B)
9% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 103
0.55% more ownership
Funds ownership: 80.06% → 80.61% (+0.55%)
1% less funds holding
Funds holding: 1,492 → 1,483 (-9)
13% less repeat investments, than reductions
Existing positions increased: 566 | Existing positions reduced: 652
19% less call options, than puts
Call options by funds: $862M | Put options by funds: $1.06B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$598M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$361M |
| 3 |
Renaissance Technologies
New York
|
+$304M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$234M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$225M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parnassus Investments
San Francisco,
California
|
-$272M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$235M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$233M |
| 4 |
JP Morgan Chase
New York
|
-$216M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$195M |
GILD Hedge Fund Activity: Q2 2019 in Review
1,483 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2019, worth a combined $70.3B — up 6.2% from $66.2B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new GILD positions and 103 closed out — a net gain of 9 holders — while 566 added to existing stakes and 652 trimmed.
The largest buyer was Nuveen, adding an estimated $598M. The largest seller was Parnassus Investments, cutting an estimated $272M.
- 1,483 institutional investors held Gilead Sciences (GILD) as of Q2 2019, down from 1,492 in Q1 2019.
- Funds reported $70.3B of Gilead Sciences stock for Q2 2019, up 6.2% quarter-over-quarter.
- 112 funds opened new Gilead Sciences positions in Q2 2019 and 103 closed out, a net change of +9 holders.
- The largest Gilead Sciences buyer in Q2 2019 was Nuveen, an estimated $598M added.
- The largest Gilead Sciences seller in Q2 2019 was Parnassus Investments, an estimated $272M sold.
Based on aggregated 13F filings for Q2 2019.